8-K: Catheter Precision Subsidiary Cardionomix Acquires Assets for Heart Failure Treatment

Catheter Precision's subsidiary, Cardionomix, acquires assets related to a late-stage heart failure treatment in development, funding the acquisition through stock issuance and a promissory note.

Summary

• Catheter Precision's subsidiary, Cardionomix, acquired assets related to a late-stage treatment for acute decompensated heart failure.
• The assets, consisting of patents and trademarks related to the Cardiac Pulmonary Nerve Simulation (CNPS) System, were acquired from Cardionomic (assignment for the benefit of creditors), LLC.
• The acquisition closed on May 5, 2025.
• The consideration included 1,000,000 restricted shares of Catheter Precision's common stock and a $1.5 million promissory note.
• The note carries a 4% annual interest rate and matures on May 5, 2028.
• Cardionomix needs to raise funds to develop the acquired assets.
• The company has begun discussions with potential investors, but there is no guarantee of securing sufficient funding.
• Future financing is likely to dilute Catheter Precision's ownership in Cardionomix.
• Minority interests in Cardionomix were issued to David Jenkins, FatBoy Capital L.P., and certain business associates of Mr. Jenkins to compensate these persons for bringing this business opportunity to the Company.

Sentiment

Score: 5

Explanation: The announcement is neutral. While the acquisition itself is a positive step, the need for additional financing and potential dilution create uncertainty.

Positives

• The acquisition provides Catheter Precision with assets related to a late-stage treatment for acute decompensated heart failure, potentially expanding its product portfolio.
• The promissory note allows Cardionomix to defer cash payments until the maturity date in 2028.
• The company has begun discussions with potential investors to secure funding for the development of the acquired assets.

Negatives

• Cardionomix has no significant assets other than the Purchased Assets.
• Cardionomix needs to raise funds to develop the acquired assets, and there is no guarantee of securing sufficient funding.
• Future financing is likely to dilute Catheter Precision's ownership in Cardionomix.
• The acquired assets were purchased on an 'AS IS' and 'WHERE IS' basis, with no representations or warranties.

Risks

• There is no guarantee that Cardionomix will be able to raise sufficient funds to develop the acquired assets.
• Future financing is likely to dilute Catheter Precision's ownership in Cardionomix and may grant corporate governance rights to other investors.
• The company may not be able to maintain protection of the patents and trade names related to the acquired assets.
• FDA review of the assets is likely to be costly and lengthy, and there is no guarantee of clearance and approval.
• The medical device industry is highly competitive, and the acquired assets must compete against existing and potential new therapies.
• The company does not have sufficient liquidity to fund its business unless it is able to obtain additional financing or enter into a strategic transaction that would provide additional liquidity during the next three months.

Future Outlook

The company plans to seek additional financing for Cardionomix to develop the acquired assets and for Catheter Precision's ongoing operations and research and development.

Industry Context

The acquisition positions Catheter Precision in the neuromodulation therapy space for heart failure treatment, a competitive area with established players and alternative therapies in development.

Related Party Transactions

• Minority interests in Cardionomix were issued to David Jenkins, FatBoy Capital L.P., and certain business associates of Mr. Jenkins to compensate these persons for bringing this business opportunity to the Company.

Stakeholder Impact

• Shareholders may experience dilution if additional equity is issued to fund Cardionomix.
• The acquisition could potentially benefit patients suffering from acute decompensated heart failure if the acquired technology is successfully developed and commercialized.

Next Steps

• Cardionomix will seek additional financing to develop the acquired assets.
• The company will continue discussions with potential investors.
• The company will pursue FDA review and approval of the acquired assets.

Key Dates

Keywords

acquisition, Cardionomix, Catheter Precision, heart failure, CNPS System, asset purchase, financing, promissory note, dilution, medical device